Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials

AIM: To evaluate 26 weeks of liraglutide treatment in type 1 diabetes (T1D) by subgroups in the ADJUNCT ONE and ADJUNCT TWO trials. MATERIALS AND METHODS: ADJUNCT ONE and ADJUNCT TWO were randomized controlled phase 3 trials in 1398 and 835 participants with T1D treated with liraglutide (1.8, 1.2, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dejgaard, Thomas F., von Scholten, Bernt J., Christiansen, Erik, Kreiner, Frederik F., Bardtrum, Lars, von Herrath, Matthias, Mathieu, Chantal, Madsbad, Sten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292057/
https://www.ncbi.nlm.nih.gov/pubmed/34463425
http://dx.doi.org/10.1111/dom.14532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292057/
https://www.ncbi.nlm.nih.gov/pubmed/34463425
http://dx.doi.org/10.1111/dom.14532

Ejemplares similares